In their study, Yogarajah et al. reported that a patient with ABCA12-deficiency-related autosomal recessive congenital ichthyosis (ARCI) experienced a 48% decrease in Ichthyosis Area Severity Index (IASI) within six months after starting to use secukinumab, an IL-17A inhibitor [62]. Here, IL17A is linked to autosomal recessive congenital ichthyosis.